The effects of epinephrine infusion in patients with von Willebrand's disease.

F R Rickles, …, M E Rick, D J Ahr

*J Clin Invest.* 1976;57(6):1618-1625. [https://doi.org/10.1172/JCI108432](https://doi.org/10.1172/JCI108432).

Research Article

Epinephrine infusion causes variable increases in the components of the Factor VIII (antihemophilic factor) complex in patients with von Willebrand's disease. The increase in antihemophilic factor procoagulant activity was greater than that of Factor VIII-related antigen and von Willebrand factor activity in two patients with von Willebrand's disease. Similar increases in the three individual factors were demonstrated in two other patients. A 4-10-fold increase in Factor VIII-related properties was identified in each of these individuals after infusion. One patient has been studied with very severe von Willebrand's disease; none of the Factor VIII-related properties increased despite two infusions of epinephrine. Bleeding times were normalized or remained normal in the two patients whose von Willebrand factor activity was greater than 25 U/100 ml. It remained prolonged in those three patients whose von Willebrand factor activity levels remained below that concentration. The increase in procoagulant activity was transient in all patients and t 1/2 values were estimated to be between 0.8 and 3.4 h.

Find the latest version:

[http://jci.me/108432-pdf](http://jci.me/108432-pdf)
The Effects of Epinephrine Infusion in Patients with Von Willebrand's Disease

FREDERICK R. RICKLES, LEON W. HOYER, MARGARET E. RICK, and DAVID J. AHR with the technical assistance of JEANNIE CHIN

From the Department of Hematology, Walter Reed Army Institute of Research, Walter Reed Army Medical Center, Washington, D. C. 20012, the Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut 06032, and the Medical Service, Veterans Administration Hospital, Newington, Connecticut 06111

ABSTRACT Epinephrine infusion causes variable increases in the components of the Factor VIII (antihemophilic factor) complex in patients with von Willebrand's disease. The increase in antihemophilic factor procoagulant activity was greater than that of Factor VIII-related antigen and von Willebrand factor activity in two patients with von Willebrand's disease. Similar increases in the three individual factors were demonstrated in two other patients. A 4-10-fold increase in Factor VIII-related properties was identified in each of these individuals after infusion. One patient has been studied with very severe von Willebrand's disease; none of the Factor VIII-related properties increased despite two infusions of epinephrine. Bleeding times were normalized or remained normal in the two patients whose von Willebrand factor activity was greater than 25 U/100 ml. It remained prolonged in those three patients whose von Willebrand factor activity levels remained below that concentration. The increase in procoagulant activity was transient in all patients and t1/2 values were estimated to be between 0.8 and 3.4 h.

INTRODUCTION
Most patients with von Willebrand's disease (VWD) have reduced plasma levels of antihemophilic factor pro-

1 Abbreviations used in this paper: Factor VIII (antihemophilic factor, AHF), general term for the plasma protein; VIIIAGN, antigen which precipitates with rabbit antibody prepared against human factor VIII; VIIIHF, clot-

coagulant activity (VIIIHF), antihemophilic factor antigen (VIIIAGN), and von Willebrand factor activity (VIIIWF) (1). In addition, patients with VWD generally manifest abnormal bleeding times, diminished retention of their platelets to glass bead filters, and a characteristic delayed response to transfusion with plasma or antihemophilic factor (Factor VIII) concentrates (2-7).

Although it has both practical and conceptual importance, the cause of the sustained rise in VIIIWF after transfusion in VWD, greater than that calculated from the quantity of VIIIWF transfused, is not understood (4-7). Previous studies have suggested that this posttransfusion VIIIWF has physicochemical (8) and procoagulant (4-7) properties like those of normal plasma Factor VIII. While susceptible to inactivation by both human and rabbit anti-Factor VIII antibodies (9), it has been reported that the "stimulated Factor VIII" does not precipitate with rabbit anti-Factor VIII (9, 10), an observation which suggests an incomplete Factor VIII may be produced in these patients. Studies in our laboratory (11) and elsewhere (10, 12, 13), have shown variable responses after transfusion of plasma or cryoprecipitate in these patients, however; these differences may reflect differences in the nature or quantity of infused materials or, perhaps, inherent variability among patients with VWD.

VIIIWF rises in response to a variety of acute and chronic stimuli in patients who do not have VWD (14—

promoting activity of factor VIII; VIIIWF, von Willebrand factor, identified in plasma as the activity which supports the aggregation of washed platelets by ristocetin (1); VWD, von Willebrand's disease.
A proportional increase in VIII\textsubscript{LON} has usually been identified (21-24), although discrepancies have been noted in liver disease (25, 26), renal disease associated with uremia and myocardial infarction (26), where disproportionately high levels of VIII\textsubscript{LON} have been demonstrated in some, but not all, cases. VIII\textsubscript{MIF} rises in patients with VWD in response to exercise or adrenaline, (15-17), as it does in normal individuals (14-16, 18-24), but there is no information regarding VIII\textsubscript{LON} or VIII\textsubscript{MIF} in these patients.

We report here studies of VIII\textsubscript{MIF}, VIII\textsubscript{LON}, and VIII\textsubscript{MIF} in patients with VWD given infusions of epinephrine hydrochloride in an attempt to characterize the "stimulated AHF" under conditions which are not complicated by the presence of exogenous plasma proteins. They demonstrated that epinephrine induces a marked increase in VIII\textsubscript{MIF}, with a lesser rise in VIII\textsubscript{LON} and VIII\textsubscript{MIF} in some patients with mild and moderate VWD; no response was detected in severe VWD.

METHODS

Patients with known VWD and normal cardiovascular and renal function were hospitalized on the Lawrence Kyle metabolic ward of the Walter Reed Army Medical Center or at the University of Connecticut Health Center. Complete bed rest was enforced during the study and patients were prohibited from smoking, ingesting coffee, tea, cocoa, or other caffeinated beverages. All patients were instructed to avoid the use of oral contraceptive agents, corticosteroids, or other agents known to affect VIII\textsubscript{MIF} levels (7). Informed consent was obtained from all patients and the protocol was approved by the human experimentation committees of both medical centers.

Patients were sedated with 100 mg of secobarbital the evening before the study. All blood samples were obtained with the patients in the supine position utilizing a no. 19 gauge scalp vein needle and polypropylene syringe. A slow infusion of 5% dextrose in water was maintained through the needle to keep it patent and 2 ml of blood-glucose solution was discarded before drawing each specimen.

Epinephrine hydrochloride (Parke, Davis and Co., Detroit, Mich.) in 23.4-77 ml of 0.9% saline, a total dose of 0.0042 mg/kg, was infused at a constant rate by infusion pump (Harvard Apparatus Co., Inc., Millis, Mass.) over 30 min. A mean pulse rate increase of 33 beats/min was observed and systolic pressure increased 38 mm Hg. Cardiac rhythm was monitored throughout the experiment and symptoms were limited to mild anxiety, palpitations, and peripheral vasconstriction. A brief period of atrial-ventricular dissociation was noted in one patient (H. E.) but disappeared immediately upon discontinuation of the infusion. No other dysrhythmias were noted.

Blood was collected into a buffered citrate solution containing 0.1 M sodium citrate (three parts) and 0.1 M citric acid (two parts) with a pH of 5.1 (nine parts blood: one part anticoagulant) in polypropylene tubes (Falcon Plastics, Oxnard, Calif.) and immediately centrifuged (12,500 g) at 4°C for 20 min. Citrated plasma was assayed immediately for VIII\textsubscript{MIF} by a modification of the one stage activated partial thromboplastin time assay (27) utilizing Platelet-Plus-Activator (General Diagnostics, Morris Plains, N. J.) and naturally deficient substrate on a Clot-Tek clot timer (Hyland Div., Travenol Laboratories, Inc., Costa Mesa, Calif.) as previously described (28). Sample plasmas for other assays were frozen immediately in dry ice and acetone and stored at −70°C. VIII\textsubscript{LON} and VIII\textsubscript{MIF} were determined on frozen samples by radioimmunoassay (29) and the washed platelet-ristocetin (Abbott Laboratories, North Chicago, III.) assay (1). Bleeding times were determined by the method of Mielke et al. (30); the normal range in our laboratory is 2-6 min. Plasma samples containing the post-infusion peak VIII\textsubscript{MIF} levels were chromatographed on 6% agarose (Bio-Gel A5M, Bio-Rad Laboratories, Richmond, Calif.) using a 1.6 × 28-cm column (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.) at an elution rate of 20 ml/h. 2-ml fractions were collected using barbital-saline (7.3 g NaCl, 2.76 g barbital, 2.06 g Na barbital/liter, pH 6.8) as the eluting buffer. VIII\textsubscript{MIF} in column fractions was determined by the method of Breckenridge and Ratnoff (31). All assays of the Factor VIII properties (VIII\textsubscript{MIF}, VIII\textsubscript{LON}, VIII\textsubscript{MIF}) are expressed as units/100 ml. A frozen pool prepared from plasmas from 20 individuals with no history of bleeding disorders was used as standard in these studies and is designated as having 100 U/100 ml of each property.

The sucrose density gradient methods have been described (32). Briefly, 13.5 ml continuous 10-40% sucrose density gradients were prepared in imidazole-saline (0.02 M imidazole, 0.14 M NaCl, pH 7.4). Whole plasma (0.75 ml) was applied to gradients which were centrifuged for 27 h at 201,800 g at 4°C using an SW 40 head. Recovery of VIII\textsubscript{MIF} and VIII\textsubscript{LON} exceeded 75%. Samples were assayed for VIII\textsubscript{MIF} at 1:6 dilutions or greater (32).

RESULTS

Table I summarizes the clinical and laboratory features of the five patients who have been studied. One patient (W. H.) had mild clinical bleeding with only a modest increase in bleeding after surgical challenge. Three (D. K., M. H., and C. P.) had evidence of moderate clinical bleeding (epistaxis, menometrorrhagia, and transfusions after minor surgical procedures) and one (H. E.) had clinically severe bleeding (spontaneous hemarthroses). Except in H. E., the severity of the bleeding disorder did not correlate well with the levels of the several components of the Factor VIII complex.

The response to epinephrine infusion was similar in patients W. H. (Fig. 1) and D. K. (Fig. 2). An immediate and transient rise of VIII\textsubscript{MIF}, VIII\textsubscript{LON}, and VIII\textsubscript{MIF} was noted and the peak values of each were approximately four times the basal levels. The three values fell rapidly after the epinephrine infusion was discontinued. The estimated t\textsubscript{1/2} values for VIII\textsubscript{MIF} were 3.1 h (W. H.) and 1.6 h (D. K.). The bleeding time became normal in patient D. K. for approximately 1 h, the greatest shortening, to 4 min, being noted immediately after the epinephrine infusion. The bleeding time remained greater than 20 min in patient W. H.

Somewhat greater increase in VIII\textsubscript{MIF} than in VIII\textsubscript{LON} or VIII\textsubscript{MIF} was noted after epinephrine infusion in patients M. H. (Fig. 3) and C. P. (Fig. 4), both of whom had equivalent levels of VIII\textsubscript{MIF} and VIII\textsubscript{LON} before epi-
TABLE I
VWD Patients

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age:Sex</th>
<th>VIIIAHF</th>
<th>VIIIAGN</th>
<th>VIIIvWF</th>
<th>Bleeding time (min)</th>
<th>Severity of clinical disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>W. H.</td>
<td>27:Male</td>
<td>23 6 5  &gt;20</td>
<td></td>
<td></td>
<td>Moderate (bleeding after tooth extraction).</td>
<td></td>
</tr>
<tr>
<td>D. K.</td>
<td>27:Female</td>
<td>30 8 &lt;5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M. H.</td>
<td>41:Female</td>
<td>47 30 43 6</td>
<td></td>
<td></td>
<td>Moderate (Bleeding requiring transfusion after minor surgery; epistaxis).</td>
<td></td>
</tr>
<tr>
<td>C. P.</td>
<td>26:Female</td>
<td>8 8 &lt;10</td>
<td>&gt;20</td>
<td></td>
<td>Moderate (Intense menometrorrhagia).</td>
<td></td>
</tr>
<tr>
<td>H. E.</td>
<td>41:Male</td>
<td>&lt;1 &lt;1 &lt;10</td>
<td>&gt;20</td>
<td></td>
<td>Severe (Spontaneous hemorrhages, etc.).</td>
<td></td>
</tr>
</tbody>
</table>

Normal range

<table>
<thead>
<tr>
<th>VIIIAHF</th>
<th>VIIIAGN</th>
<th>VIIIvWF</th>
</tr>
</thead>
<tbody>
<tr>
<td>50-155</td>
<td>60-168</td>
<td>55-130</td>
</tr>
</tbody>
</table>

nephrine infusion. C. P. (Fig. 4) had an immediate 10-fold rise of VIIIAHF but minimal response of VIIIAGN or VIIIvWF. Although all Factor VIII-related measures rose after epinephrine infusion in M. H., the magnitude of the VIIIAHF increase (ninefold; from 45 to 400 U/100 ml) and the VIIIvWF increase (eightfold; from 32 to 256 U/100 ml) was greater than that for VIIIAGN (fourfold; from 35 to 138 U/100 ml). The duration of VIIIAHF elevation in these two patients was also brief; estimated t½ values were 3.4 h in M. H. and 0.8 hours in C. P. The bleeding time was normal before epinephrine infusion in

FIGURE 1 Antihemophilic factor (Factor VIII) procoagulant activity (VIIIAHF), antigen (VIIIAGN), and von Willebrand factor activity (VIIIvWF) after epinephrine infusion in patient W. H. The plasma levels of each of these three properties are indicated on the vertical axis. Pooled normal plasma (100 U/100 ml) is the standard for each assay. Three "base-line" plasma samples were obtained with the intravenous needle in place before infusion of epinephrine. The bleeding time was recorded as >20 min before the infusion, immediately after the infusion and 45 min later.

1620  F. R. Rickles, L. W. Hoyer, M. E. Rick, and D. J. Ahr

FIGURE 2 VIIIAHF, VIIIAGN, and VIIIvWF after epinephrine infusion in patient D. K. The bleeding time was 10 min before the infusion (N = 2-6), 4½ min immediately after the infusion, 4 min at 15 min postinfusion, 17 min at 1 h, and >20 min at 2 h postinfusion.
The bleeding time was 2 min before infusion and was unchanged immediately after infusion.

M. H. and no other determinations were carried out. The bleeding time remained longer than 20 min in C. P.

Patient H. E. (Fig. 5), whose VIIIAGN level was less than 1 U/100 ml, was the most severely affected patient tested. No changes in VIIIAGN, VIIIAGN, or VIIIVWF could be detected after two separate epinephrine infusions and the bleeding time remained long (greater than 20 min).

An estimate of the molecular size of the “stimulated VIIIAGN” was obtained by agarose gel chromatography and sucrose density gradient ultracentrifugation of plasma samples stored at −70°C for 2-8 wk. Fig. 6 illustrates the chromatographic patterns found on the peak postepinephrine infusion samples of patients W. H. and D. K. Both VIIIAGN and VIIIVWF were eluted in the void volume fractions indicating a molecular weight of greater than 1.0 × 10^6 daltons. This elution pattern is the same as that previously reported for normal plasma VIIIAGN (33). A preliminary sucrose density centrifugation study has also been carried out with a postepinephrine infusion sample of patient D. K. The “stimulated VIIIAGN” was found in the same fractions as VIIIAGN in normal plasma, i.e. fractions which correspond to molecular weight of greater than 1.0 × 10^6 (32).

DISCUSSION

The response to transfusion of patients with VWD has intrigued observers since the initial description by Nilsson and co-workers in 1959 (4). Despite variability in response to transfused plasma among some patients with VWD (34), and a degree of overlap with normal individuals (35), the delayed peak and slower disappearance of VIIIAGN after plasma transfusion has been considered characteristic of this disease (4-6). The control mechanisms of this response, however, and the nature of the “stimulated VIIIAGN” remain uncertain. Although Barrow and colleagues did not detect physicochemical differences between normal VIIIAGN and “stimulated VIIIAGN” from a patient with VWD (8), recent studies have described rather marked in vitro lability of VIIIAGN when VWD plasmas are stored for short periods at −20°C (10, 36). Additionally, immunochemical methods have demonstrated that plasmas with “stim-

Epinephrine Infusion in von Willebrand’s Disease 1621
ulated VIIaFV do not have corresponding levels of VIIIa when measured by immunoprecipitation methods using rabbit antibodies (9, 10). These observations have led to the suggestion that the "stimulated VIIaFV" is indeed different from normal plasma VIIaFV. Transfusion experiments are difficult to interpret, however, because of the variable responses to different therapeutic materials (37) and the possible effects of plasma proteins other than factor VIII.

Previous studies have identified an increase in Factor VIII procoagulant activity (VIIaFV) in VWD patients given epinephrine (15, 16), a rise which is more rapid and transient than that which follows plasma transfusion (4–6). We have confirmed the rapid response
to epinephrine in this disease and have also identified an increase in VIII* and VIII**. The rapid increase of all three properties after epinephrine infusion suggests that epinephrine stimulates the release of preformed Factor VIII rather than new synthesis. Moreover, it is clear that no exogenous protein intermediate is required for the release of VIII* and VIII**, or VIII**. The identification of VIII* and VIII** in endothelial cells by immunofluorescence (38, 39), and the detection of both VIII* and VIII** in the media of cultured human endothelial cells (40, 41), suggests that the rapid effect of epinephrine may be due to Factor VIII release from endothelial cells. This interpretation is supported by the identification of VIII* in endothelial cells of superficial veins obtained by biopsy in patients with mild or moderate VWD (42). The failure to detect an epinephrine effect in patient H. E. is also consistent with this hypothesis, for VIII* was not detected in endothelial cells of patients with severe VWD (42). Based on these studies, it is conceivable that pharmacologic manipulation of Factor VIII release may be accomplished in the future without supplying exogenous plasma proteins. Long acting vasoactive drugs may be useful in the support of patients with VWD during short term surgical procedures or in the management of limited trauma. Further investigation of the mechanism of the in vivo response of Factor VIII to pharmacologic agents seems warranted.

The bleeding time remained prolonged in two of the patients studied (W. H. and C. P.) even though VIII*, VIII**, and VIII*** levels were increased after epinephrine infusion. Previous studies of the relationship of the bleeding time to VIII*** suggest that a normal bleeding time indicates VIII*** levels above a critical value estimated to be between 20 and 40 U/100 ml (1, 43). The VIII*** (and VIII**) levels remained below 25 U/100 ml during the postinfusion period in both W. H. and C. P.; the persistently prolonged bleeding time in these patients is consistent with previous studies of this relationship (1, 43). In contrast, the bleeding time shortened from 10 to 4 min after epinephrine infusion in D. K. as the VIII*** level rose to 32 U/100 ml. The correlation of bleeding time correction and VIII*** levels in D. K. differs from the findings reported by Ratnoff and co-workers for two patients with VWD. In each of these individuals the bleeding time remained long even though VIII* and VIII** rose to normal levels and the platelets aggregated normally with ristocetin (44, 45). These contrasting observations indicate the need for further careful studies of the relationship of the bleeding time and VIII*** levels in VWD.

The apparent in vivo difference in the VIII*** response from that of the VIII* and VIII** in patient C. P. (Fig. 4) must be interpreted with caution. Although it is possible that epinephrine has a differential stimulatory effect on three separate entities, the nature of these assays makes it impossible to compare the different components of the Factor VIII complex in any direct way. Each property is quantified by reference to a normal plasma pool standard and only relative concentrations can be measured. If the normal plasma standard contains different numbers of molecules of the components of the Factor VIII complex, addition of material which has the same number of molecules of each component would cause variable changes in the values measured in the three assays. The different responses of the three properties would be most apparent if only a small proportion of the Factor VIII complexes in normal plasma had VIII*** activity. If this were the case, the postinfusion changes in VIII* would be more striking if fully active molecules were released from endothelial cells by epinephrine stimulation. A similar differential response of VIII* and VIII** has been reported by Ruggeri and co-workers in their studies of a synthetic analogue of vasopressin. The basis for this differential response in plasma assay values was not discussed in their preliminary report (46).

We do not know how epinephrine causes changes in Factor VIII levels. Although this drug may effect the release of Factor VIII storage from sites, it is also possible that it may affect the Factor VIII molecule, either directly or indirectly. Transient thrombin generation, for example, would increase VIII*** without affecting VIII* or VIII**, i.e., VIII*** could be “activated” (46-49). Postinfusion VIII*** appears to be very large, however, (Fig. 6), an observation which is not consistent with the changes in the sedimentation and chromatographic properties which have been described for thrombin-activated Factor VIII (50, 51). Further assessment of the possible role of thrombin generation during epinephrine infusion and of the properties of the “stimulated AHF” are in progress.

The pattern of Factor VIII related measurements after epinephrine infusion in C. P. (Fig. 4), normal VIII*** with very low VIII** and VIII*, is similar to that which has been identified after plasma or cryoprecipitate infusion in VWF (9, 10). Material which has VIII*, and which has very low VIII** and VIII**, has also been identified in in vitro studies in which Factor VIII is exposed to high ionic strength buffers (32, 47). Although this similarity is of great interest, its significance is uncertain. Since VIII*** obtained in high salt separations appears to have a lower molecular weight than the other components of the Factor VIII complex, we have examined the properties of “stimulated VIII***” on agarose gel chromatography and sucrose density gradient centrifugation. Although we have not identified any low molecular weight VIII*** in
these studies, it is important to recognize the inherent problems in determining VIII:AgP size. It is possible that the properties of postinfusion VIII:AgP are modified by the association of low molecular weight material with the larger components of the factor VIII complex which are present in these plasmas. It is also possible that there is aggregation of "stimulated VIII:AgP" during storage and/or in vitro analysis.

The different patterns of response to epinephrine in these patients may correspond to differences in the molecular defects which are responsible for VWD. In the most severe form of the disease (patient H. E.), no Factor VIII could be detected, even after epinephrine stimulation; this may represent an absolute defect in synthesis. Reduced but measurable quantities of the components of the Factor VIII complex are present in patients with mild and moderate VWD. The increases detected after epinephrine stimulation suggest that some control mechanisms are present in these individuals, however, and that they are susceptible to pharmacologic modification. The relationship of this modification to possible treatment of VWD remains to be determined.

ACKNOWLEDGMENTS

The authors wish to thank Mrs. Carol Church, Miss Norma Trabold, Mr. Carl Carta, and Mr. Charles Barr for excellent technical assistance. We thank Dr. Robert T. Breckenridge for referring patient H. E. for study.

These studies were supported in part by grants HL 16626 and HL 16872 from the National Heart and Lung Institute. They represent part of the Veterans Administration project Medical Research Information System No. 7446-01.

REFERENCES

hemophilic factor (AHF, Factor VIII) procoagulant
activity and AHF-like antigen in alcoholic cirrhosis of
protein in clinical praxis. Scand. J. Haematol. 12: 221–
231.
thromboplastin time with kaolin. A simple screening
Pathol. 36: 212–219.
28. Rickles, F. R., J. A. Hardin, F. A. Pitlick, L. W. Hoyer,
and M. E. Conrad. 1973. Tissue factor activity in lym-
phocyte cultures from normal individuals and patients
29. Hoyer, L. W. 1972. Immunologic studies of antihemo-
philic factor (AHF, factor VIII). Radioimmunoasay of
30. Mielke, C. H., Jr., M. M. Kaneshiro, I. A. Maher,
J. M. Wiener, and S. I. Rapaport. 1969. The standard-
ized normal Ivy bleeding time and its prolongation by
on the nature of the circulating anticoagulant directed
against antihemophilic factor: with notes on an assay
studies of antihemophilic factor (AHF, Factor VIII).
V. Immunologic properties of AHF subunits produced
on the purification of antihemophilic factor (Factor
VIII). II. Separation of partially purified antihemophilic
factor by gel filtration of plasma. J. Clin. Invest. 48:
957–962.
34. Levin, J., and D. P. Jackson. 1968. Variable responsi-
Proc. Congr. 7th, 177.
35. Meyer, D., M. J. Larrieu, P. Maroteaux, and J. B.
Caen. 1967. Biological findings in von Willebrand pedi-
(Lond.), 20: 190–194.
36. Bowie, E. J. W., D. N. Fass, J. D. Olson, and C. A.
Owen, Jr. 1974. Transfusion and autotransfusion of
plasma in von Willebrand's disease. Thromb. Res. 5:
479–494.
37. Perkins, H. A. 1967. Correction of the hemostatic de-
Antihemophilic factor antigen. Localization in endothelial
52: 2737–2744.
Factor VIII on the vascular intima: possible importance
in haemostasis and thrombosis. Nat. New Biol. 241:
Synthesis of antihemophilic factor antigen by cultured
Synthesis of von Willebrand factor by cultured human
1906–1909.
42. Holmberg, L., P. M. Mannucci, I. Turesson, Z. M. Rug-
geri, and I. M. Nilsson. 1974. Factor VIII antigen in
the vessel wall in von Willebrand's disease and hemophi-
pathogenesis of bleeding in von Willebrand's disease.
46. Ruggeri, Z. M., F. I. Paretì, P. Bintadish, and P. M.
Mannucci. 1974. Clotting factors in von Willebrand's
factor: dissociation from antihemophilic factor pro-
1151.
Ames. 1963. The importance of activation of antihemo-
philic globulin and proaccelerin by traces of thrombin
in the generation of intrinsic prothrombinase activity.
26: 500–509.
antiahaemophilic globulin in plasma, cryoprecipitate and
51. Cooper, H. A., F. F. Reisner, M. Hall, and R. H.
Wagner. 1975. Effects of thrombin treatment on prepa-
ration of factor VIII and the Ca²⁺-dissociated small